Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories (NYSE: RDY) announced the commercial launch of olanzapine tablets, an antipsychotic medication.


Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories, olanzapine tablets, Zyprexa generic, Zyprexa, antipsychotic medication, generic version, Eli Lilly




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Teva, Dr. Reddy's introduce Zyprexa generic

October 25th, 2011

HYDERABAD, India – Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories (NYSE: RDY) announced the commercial launch of olanzapine tablets, an antipsychotic medication.

The companies said Tuesday that Teva's olanzapine tablets in dosages of 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg and Dr. Reddy's 20-mg olanzapine tablets have each been awarded a 180-day period of marketing exclusivity in the United States.

Dr. Reddy's is supplying the 20-mg version of the product under an April 2011 commercialization, manufacture and supply pact with Teva. In addition, through the agreement, Dr. Reddy's will launch its 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg olanzapine tablets upon the expiration of the 180-day exclusivity period.

Olanzapine is used to treat the symptoms of such conditions as schizophrenia and bipolar disorder.

According to Teva and Dr. Reddy's, the products are a generic version of Eli Lilly's Zyprexa. Annual U.S. sales of Zyprexa totaled approximately $3.2 billion as of September 2011, based on IMS Health sales data cited by Teva and Dr. Reddy's.

Advertisement